Recent Updates
Recently added Catalysts
ORKA Neutral Sentiment

Recent Developments Certain Financial and Operating Data for First Quarter 2026 While we have not finalized our full financial results for the quarter ended

Key Takeaway: The article discusses the preliminary financial data for ORKA for the first quarter of 2026, highlighting an estimated cash, cash equivalents, and investments totaling approximately $496 million as of March 31, 2026. It underscores that these figures are not yet finalized and are subject to revision based on the closing of accounting records. The report emphasizes that the data has not been audited or reviewed by PricewaterhouseCoopers LLP, indicating a need for caution in relying on this preliminary estimate.
Price reaction · baseline $68.1 (2026-04-29 close) · hit after-hours · clean, no other ORKA news in the window
day 0 close
+0.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • Financial results for Q1 2026 are not finalized yet.
  • Preliminary estimates are subject to revision and may not reflect final results.
  • Lack of audit by PricewaterhouseCoopers LLP raises concerns over data reliability.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+307%
120-day peak, hindsight
Typical move
13%
average across 4 past catalysts
Cash runway
~102 mo
Minimal dilution risk
Lead asset
ORKA-001
Phase 2 · Plaque Psoriasis

Full Press Release Details

Certain Financial and Operating Data for First
While we have not finalized our full financial
results for the quarter ended March 31, 2026, we estimate that our cash, cash equivalents, and investments were approximately $496 million
as of March 31, 2026.
This preliminary estimate is based on currently
available information and is subject to revision based upon, among other things, the finalization and closing of our accounting books
and records. Our financial results for the three months ended March 31, 2026 are not yet finalized.
The preliminary financial data included in this
prospectus supplement has been prepared by, and is the responsibility of, our management. PricewaterhouseCoopers LLP has not audited,
reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers
LLP does not express an opinion or any other form of assurance with respect thereto. This estimate should not be viewed as a substitute
for financial statements prepared in accordance with accounting principles generally accepted in the United States and is not necessarily
indicative of the results to be achieved in any future period. Accordingly, you should not draw any conclusions based on the foregoing
estimate and should not place undue reliance on this preliminary estimate.

Frequently Asked Questions

What was the estimated cash position as of March 31, 2026?

The estimated cash, cash equivalents, and investments were about $496 million.

Are the financial results for March 31, 2026 finalized?

No, the financial results for the quarter ended March 31, 2026, are not finalized.

Who prepared the preliminary financial data?

The preliminary financial data was prepared by the management team.

Has PricewaterhouseCoopers audited the preliminary data?

No, PricewaterhouseCoopers has not audited or reviewed the preliminary financial data.

Can the preliminary estimate be relied upon?

No, this preliminary estimate should not be relied upon or substituted for official financial statements.

Last updated: Apr 30, 2026